Special Issue "Novel Therapeutic Treatments to Target Glioblastoma Intratumoral Heterogeneity and Plasticity"
Deadline for manuscript submissions: 1 December 2021.
Interests: brain tumors; precision oncology; patient-derived organoids; transcriptomics; proteomics; deep learning; microscopy; brain disorders
Special Issues and Collections in MDPI journals
Glioblastoma multiforme (GBM) is the most aggressive type of brain cancer with a 5-year relative survival (4.6% only at 5 years) that has remained stable over the last 3 decades. Intratumour heterogeneity is a key feature that makes GBM one of the most deadly types of tumours, which results from the capacity of GBM-cancer stem cells to inter-convert between different cancer cell populations in response to changes in the tumour microenvironment and/or different drug treatments. This not only explains the poor performance in single drug therapy in GBM, but also reveals a key role for GBM plasticity, the interaction of GBM and the microenvironment and brain cancer progression, and thus constitutes a novel paradigms that needs to be addressed in order to find better treatments for patients with GBM.
This special issue will be dedicated to publish original work and reviews in the areas of neuro-oncology, pharmacology, bioinformatics, cell and cancer biology, drug-screenings, bioengineering, genetics, and others, on aspects that will contribute to better understanding at the molecular level of the functional role of heterogeneity and plasticity in glioblastoma biology and treatment.
Dr. Guillermo Gomez
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cancer stem cells
- immune system
- cancer cell resistance
- perivascular niche
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
- Tentative Title: Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: Review of Current Evidence and Future Applications
Authors: D. Zhao, Z.P. Zhuang, H.R. Wang, R. Medina
2. Tentative Title: The role of inhibitors for the G protein coupled receptor CCR5- and functional synergy with current cancer therapies.
Authors: Richard Pestell; Tamara Lah Turnšek
3. Tentative Title: Novel conception for glioblastoma therapy regarding its heterogeneity
Authors: Gábor Hutóczki, József Virga, András Szökőcs, Zsuzsanna Birkó, Álmos Klekner
4. Tentative Title: An integrated bioinformatics study of a novel niclosamide derivative NSC765689 as an anti-glioblastoma agent by suppressing GSK3β/β-catenin/STAT3/CD44 signaling while upregulating the tumor suppressor miR-135b.
Authors: Ntlotlang Mokgautsi, Bashir Lawal, Harshita Khedkar, Maryam rachmawati Sumitra, Alexander T.H Wu , Hsu-Shan Huang
5.Tentative Title: The prognostic role of endoglin (CD105) in recurrent glioblastoma patients submitted to antiangiogenic therapy
Author: Metka Novak
6. Tentative Title: Therapeutic and prognostic significance of c-Met, HGF, VEGFR2 and CD31 in bevacizumab-treated glioblastomas
Authors: Bruno Carvalho, António Bastos, Vasco Carvalho, Roberto Silva, Dina Leitão, Paulo Linhares, Rui Vaz, Jorge Lima
7.Tentative Title: The molecular clock as a new target for glioblastoma treatment
Authors: Paula M. Wagner, César G. Prucca, Beatriz L. Caputto and Mario E. Guido